Re: [caret-users] caret docs; Display Control especially

2006-11-07 Thread Graham Wideman

Donna:

A belated thanks for the reply...


Burying your head in David's PALS paper is indeed the best way


.. belated because I was on a hastily-arranged trip to the UK, during which 
I avoided having too short of a plane ride...



(And you can't whip through in a short plane ride.)


So now I'm a lot more up to speed (not to mention jet-lagged).

Thanks again for your replies and suggestions.

Graham



Re: [caret-users] caret docs; Display Control especially

2006-10-31 Thread Donna Dierker

Hi Graham,

Burying your head in David's PALS paper is indeed the best way to get 
your head around this stuff.  It took me three careful reads before I 
really digested it.  (And you can't whip through in a short plane ride.)


To get a more hands-on feel for Caret/SureFit surfaces, consider
downloading and playing with these datasets in Caret:

PALS_VE05_FIG-11_FMRI_MFMapping.73730.spec
From PALS paper, figure 11
http://sumsdb.wustl.edu/sums/archivelist.do?archive_id=6334372

Human.PALS.VE-et-al_JN06_WILLIAMS_Suppl_Fig-1_Volumes_Fiducials.spec
From WS paper (http://www.jneurosci.org/cgi/content/full/26/20/5470),
supplementary figure 1
http://sumsdb.wustl.edu/sums/archivelist.do?archive_id=6473226

Also, notice in David's email replies:  You have taught him to say
voxel-wise statistics rather than volume-averaged fMRI results --
well done!

When mapping to the PALS_B12 surfaces, there's plenty of uncertainty to
go around.  Increasingly, there's consensus that reconstructing
individual surfaces and doing one's analysis in surface-land is an 
excellent complement to voxelwise-statistics for most cortical studies. 
 But for the majority of researchers not yet prepared to do so, this 
atlas is a useful visualization substrate for their group results.


Questions about which mapping method to use are valid, and reasonable
people can disagree about such things, but as you say, it's relatively
in the noise compared to what I would call doing it right.

Another source of variability stems from the degree to which the
PALS_B12 average fiducial surface represents your sample's average
anatomy well.  In a joint study with Dr. Csernansky and Deanna Barch's
lab, the PALS_B12 average fiducial represents the CONTROLS' anatomy 
well, but schizophrenics' anatomy less well.  Anatomical differences 
across groups almost certainly contribute (even where they may not quite 
reach statistical significance by our conservative method).  In the 
attached captures, the structural underlay is a mean SCZ volume for 
SCZ13anat_SFSdiff.jpg, mean CONTROL volume for CON19anat_SFSdiff.jpg. 
In both captures, the blue contour is the average CON fiducial (sample 
subjects -- not PALS_B12); the red contour is the average SCZ fiducial. 
 Not shown, the CON average fiducial overlaps the PALS_B12 fiducial 
much better than does the SCZ average fiducial.  Of course, you don't 
know how good a proxy PALS_B12 is for your sample unless you reconstruct 
all your subjects.  (Thanks to Dr. Lei Wang and Dr. Deanna Barch for 
allowing use of their prepublication data.)


On 10/27/2006 12:39 AM, Graham Wideman wrote:

David:


Further, my superficial understanding of MFM worries me that a weak
activation caught by all surfaces might produce the same appearance
as strong activation caught by only a small proportion of the MF
surfaces.


That is indeed possible.  However, this isn't necessarily a bad
thing.  Moreover, the same thing can occur during volume-based
statistical analyses - a voxel that shows weak but consistent
activation may show the same z-statistic as a voxel that has a strong
activation in a small proportion of individuals.


Not sure if it's important, but these seem somewhat different cases. 
In the voxel-based situation the confounding obscures the difference 
between a few strong activations vs many weak activations.


In the MFM situation, the confounding is at a subsequent stage: this 
is not about muddling strong and weak activations, but rather it's 
about the sampling strategy (fMRI-surface mapping) being more or less 
sensitive in different regions, depending on the variability of the MF 
surfaces in that region (ie: how many of the MF surfaces intersect an 
activation).


But all this may be relatively in the noise, I guess, compared to 
using surfaces derived from each individual subject.


(Again, time to read the paper in detail, and see in what ways you've 
been able to characterize the sensitivity of generic MFM vs using 
subjects' own surfaces.).


All very interesting.

Graham

--

Donna L. Dierker
(Formerly Donna Hanlon; no change in marital status -- see 
http://home.att.net/~donna.hanlon for details.)



inline: SCZ13anat_SFSdiff.jpginline: CON19anat_SFSdiff.jpg

Re: [caret-users] caret docs; Display Control especially

2006-10-27 Thread David Vanessen

Graham,

On Oct 26, 2006, at 11:37 PM, Graham Wideman wrote:

.
Good!  The issue of whether the average fiducial surface  
intersects various blobs of activation is an important one. [...]


Right -- that all sounds good.  What I'm not yet convinced about  
intuitively is that the average surface should have this relatively  
in board position. If that's the way it is, then so be it,  of  
course!


Bear in mind that voxel-wise statistical analyses on group data tends  
to favor activations that are somewhat internal to the margins of the  
hemisphere.   Hence, the significant activation centers will  
inherently tend to occur close to the average fiducial surface.


Further, my superficial understanding of MFM worries me that a weak  
activation caught by all surfaces might produce the same appearance  
as strong activation caught by only a small proportion of the MF  
surfaces.


That is indeed possible.  However, this isn't necessarily a bad  
thing.  Moreover, the same thing can occur during volume-based  
statistical analyses - a voxel that shows weak but consistent  
activation may show the same z-statistic as a voxel that has a strong  
activation in a small proportion of individuals.


But perhaps that's all dealt with in the math, and I know that  
there are also several mapping strategies in caret's fMRI-to- 
surface mapping procedure.


It's in the nature of how statistical significance is assessed.


Anyhow, time to scrutinize your paper in more detail (not just the  
pictures :-).


Good - again!

David



Graham
___
caret-users mailing list
caret-users@brainvis.wustl.edu
http://pulvinar.wustl.edu/mailman/listinfo/caret-users




[caret-users] caret docs; Display Control especially

2006-10-23 Thread Graham Wideman

Folks:

We are trying to get up to speed on caret, and find ourselves thoroughly 
stalled by holes in the docs, but suspecting that we may be missing some 
important doc.


In particular, we really need a guide as to what everything in the UI 
actually does.


Case in point:

Display Control dialog:  There's a great deal of functionality there, but 
rather inscrutable without docs:  The GUI Reference Guide doesn't list the 
Display Control dialog, so has this not been documented, or is it 
documented somewhere else?


We want to know, for example, how to operate the Metric  Threshold 
settings. There are Column, Average Area and User widgets -- what are they 
all about?  We're pretty certain that they somehow filter or color the data 
to be displayed, but how is not clear.


Thanks,

Graham